Meghan Scanlon - 27 Jul 2021 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)

Role: SVP,Pres,Urology Pelvic Health
Signature: /s/ Vance R. Brown, Attorney-in-fact
Issuer symbol: BSX
Transactions as of: 27 Jul 2021
Net transactions value: -$299,160
Form type: 4
Filing time: 27 Jul 2021, 20:28:48 UTC
Previous filing: 06 Jul 2021
Next filing: 04 Aug 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BSX	Common Stock	Options Exercise	$324,228	+13,850	+72%	$23.41	32,992	27 Jul 2021	Direct	F1, F2
transaction	BSX	Common Stock	Sale	$623,388	-13,850	-42%	$45.01	19,142	27 Jul 2021	Direct	F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BSX	Stock Option (Right to Buy)	Options Exercise	$0	-13,850	-100%	$0.000000^*	0	27 Jul 2021	Common Stock	13,850	$23.41	Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.
F2	Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.
F3	Represents the weighted average sale price. These shares were sold in multiple transactions at $45.00 and $45.02. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4	Grant to the reporting person of an option to purchase 13,850 shares of common stock vesting in four equal annual installments beginning on July 1, 2017, the first anniversaryof the date of grant.